Xenofon Baraliakos
YOU?
Author Swipe
View article: Comparison of radiographic spinal changes and their progression in patients with axial spondyloarthritis vs. psoriatic arthritis with inflammatory axial involvement
Comparison of radiographic spinal changes and their progression in patients with axial spondyloarthritis vs. psoriatic arthritis with inflammatory axial involvement Open
Background Psoriatic arthritis with inflammatory axial involvement (PsA-ax) and axial spondyloarthritis (axSpA) are distinct entities within the spectrum of spondyloarthritides. Despite overlapping clinical and imaging features, the extent…
View article: Frequency of difficult-to-manage and treatment-refractory axial SpA: insights from the German RABBIT-SpA register using recent ASAS definitions
Frequency of difficult-to-manage and treatment-refractory axial SpA: insights from the German RABBIT-SpA register using recent ASAS definitions Open
Objectives To determine the frequency of axial spondyloarthritis (axSpA) patients fulfilling the recently proposed Assessment of SpondyloArthritis International Society (ASAS) definitions for difficult-to-manage (D2M) and treatment-refract…
View article: Rheumatologist and patient perspectives on axial spondyloarthritis management and treatment satisfaction in Europe
Rheumatologist and patient perspectives on axial spondyloarthritis management and treatment satisfaction in Europe Open
Patients and their rheumatologists were moderately aligned on their perception of disease severity and treatment satisfaction but differed in their expectations regarding treatment target. The study highlights the need for ongoing involvem…
View article: Effectiveness and Safety of Upadacitinib in Treating Oligoarticular and Polyarticular Psoriatic Arthritis: Primary Analysis from the UPJOINT-Study
Effectiveness and Safety of Upadacitinib in Treating Oligoarticular and Polyarticular Psoriatic Arthritis: Primary Analysis from the UPJOINT-Study Open
NCT04758117 (ClinicalTrials.gov).
View article: Digital Behavioral Therapy Improves Outcome in Patients With Axial Spondyloarthritis and Persistent Pain: A Randomized Controlled Trial
Digital Behavioral Therapy Improves Outcome in Patients With Axial Spondyloarthritis and Persistent Pain: A Randomized Controlled Trial Open
Objective Axial spondyloarthritis (axSpA) is often associated with persistent pain despite effective anti‐inflammatory treatment. Digital health applications (DHAs) provide innovative approaches to address multidimensional aspects of persi…
View article: Evaluation of spondyloarthritis-specific health utility based on ASAS health index (U-ASAS-HI) among the disease subtypes: an ancillary analysis from the ASAS-PerSpA study
Evaluation of spondyloarthritis-specific health utility based on ASAS health index (U-ASAS-HI) among the disease subtypes: an ancillary analysis from the ASAS-PerSpA study Open
Objectives To compare the spondyloarthritis (SpA) specific universal health utility estimation from the ASAS health index (U-ASAS-HI) with the generic EuroQol-5D-3L (EQ-5D-3L) utility among SpA subtypes and to understand the contribution o…
View article: ASAS recommendations on reporting axial spondyloarthritis clinical trials
ASAS recommendations on reporting axial spondyloarthritis clinical trials Open
These ASAS-endorsed recommendations on axSpA clinical trial reporting provide a standardised approach to reporting both baseline features as well as outcomes from axSpA clinical trials.
View article: Combination targeted therapy with two biologic/targeted synthetic DMARDs in 1200 patients with immune mediated inflammatory diseases. A systematic literature review for current landscape in safety and efficacy
Combination targeted therapy with two biologic/targeted synthetic DMARDs in 1200 patients with immune mediated inflammatory diseases. A systematic literature review for current landscape in safety and efficacy Open
CTT benefits about half of refractory IMID patients, particularly TNFi/IL-23i, JAKi/bDMARD, and vedolizumab/TNFi combinations, without raising significant safety issues. Further research is needed to clarify safety and efficacy across dise…
View article: Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study
Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study Open
Here, 30 mg and 15 mg zasocitinib demonstrated efficacy across core domains in patients with active PsA with no new safety signals. These findings will be confirmed in ongoing larger studies of longer duration.
View article: Bimekizumab Maintained Stringent Clinical Responses Over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Bimekizumab Maintained Stringent Clinical Responses Over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies Open
Objectives To assess the maintenance of response to bimekizumab (BKZ) among patients (pts) across the full disease spectrum of axial spondyloarthritis (axSpA) over 2 years in the open-label extension (OLE) of BE MOBILE 1 and 2. Methods BE …
View article: Longitudinal association of early axial spondyloarthritis status at the time of diagnosis with disease activity over time: 10-year results from the GESPIC cohort
Longitudinal association of early axial spondyloarthritis status at the time of diagnosis with disease activity over time: 10-year results from the GESPIC cohort Open
Objective Recently, the definition for ‘early axial spondyloarthritis (axSpA)’ was developed by the Assessment of SpondyloArthritis international Society (ASAS), including ≤2 years of axial symptoms as a key element. The aim of this study …
View article: Trace Element Deficiency in Axial Spondyloarthritis and Psoriatic Arthritis in Relation to Markers of Inflammation and Remission
Trace Element Deficiency in Axial Spondyloarthritis and Psoriatic Arthritis in Relation to Markers of Inflammation and Remission Open
Selenium (Se) is an essential micronutrient for antioxidant defense. Selenoproteins are involved in metabolic and signaling pathways of autoimmune and autoinflammatory diseases. Copper (Cu) and zinc (Zn) are integral components of key enzy…
View article: Radiographic structural damage in axial spondyloarthritis: is there a preferred way to quantify progression over time? Comparison of blinded versus unblinded mSASSS scoring
Radiographic structural damage in axial spondyloarthritis: is there a preferred way to quantify progression over time? Comparison of blinded versus unblinded mSASSS scoring Open
More mSASSS progression was detected using unblinded vs blinded scoring. Scoring spinal radiographs with known chronological order seems to be more sensitive to changes.
View article: OA16 Bimekizumab treatment resulted in improvements in MRI inflammatory and structural lesions in the sacroiliac joints of patients with axial spondyloarthritis: 52-week results and post hoc analyses from two Phase 3 studies
OA16 Bimekizumab treatment resulted in improvements in MRI inflammatory and structural lesions in the sacroiliac joints of patients with axial spondyloarthritis: 52-week results and post hoc analyses from two Phase 3 studies Open
Background/Aims The impact of dual inhibition of interleukin (IL)17F in addition to IL-17A with bimekizumab (BKZ) on structural lesions in axial spondyloarthritis (axSpA) patients has not yet been shown. We report BKZ impact on MRI inflamm…